Pre-close Trading Update

Advanced Medical Solutions Grp PLC
11 January 2005


For Immediate Release                                            11 January 2005




                      Advanced Medical Solutions Group plc

                            ('AMS' or 'the Company')



                            Pre-close trading update



Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global wound
care technology company, is pleased to update investors on trading ahead of the
close period for the year ending 31st December 2004.

Dr. Geoffrey Vernon, Chairman of AMS, stated: 'The progress reported at the half
year in growing revenues and reducing losses has continued during the second
half of 2004.

'The outlook remains positive, particularly following further expansion of the
Company's routes to market with its recently announced inclusion in the NHS
Framework Agreement for Advanced Woundcare in England

'The Company continues to trade in line with market expectations and remains
firmly on track to come through to profitability within current cash.'



For further information, please contact:


Advanced Medical Solutions Group plc               Tel : [phone]
Don Evans, Chief Executive
Mary Tavener, Finance Director
www.admedsol.com

Buchanan Communications                            Tel: [phone]
Mark Court, Mary-Jane Johnson




Notes to Editors:


Advanced Medical Solutions is a leading company in the development and
manufacture of products for the $15 billion global woundcare market.

Founded in 1991 and currently quoted on AIM, Advanced Medical Solutions is
focused on the design, development and manufacture of innovative and
technologically advanced products for woundcare and other medical applications.

In-house natural and synthetic polymer technology is used to provide advanced
wound dressings based on the moist healing principle. AMS's resources ensure a
unique position as a vertically integrated 'one stop shop' to provide all
categories of moist wound healing products. The Company has the capability to
move from product design and development through to production and delivery
ready for distribution into customer markets.

The acquisition of MedLogic in 2002 has brought AMS products and technology in
cyanoacrylate based tissue adhesives and sealants sold direct to hospitals or
through distributors.

AMS's technology and products currently serve the majority of the key global
markets with strategic partners including 3M, Novartis, Johnson & Johnson,
Molnlycke Healthcare,  Smith + Nephew and Cardinal.


                      This information is provided by RNS
            The company news service from the London Stock Exchange